185 related articles for article (PubMed ID: 25071013)
1. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression.
Wang FW; Cai MY; Mai SJ; Chen JW; Bai HY; Li Y; Liao YJ; Li CP; Tian XP; Kung HF; Guan XY; Xie D
Oncotarget; 2014 Aug; 5(16):6716-33. PubMed ID: 25071013
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
6. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.
Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN
Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY
Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition.
Bao Y; Zhang Y; Lu Y; Guo H; Dong Z; Chen Q; Zhang X; Shen W; Chen W; Wang X
Int J Biol Sci; 2020; 16(5):827-837. PubMed ID: 32071552
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
Tang DJ; Dong SS; Ma NF; Xie D; Chen L; Fu L; Lau SH; Li Y; Li Y; Guan XY
Hepatology; 2010 Apr; 51(4):1255-63. PubMed ID: 20112425
[TBL] [Abstract][Full Text] [Related]
12. Notch4 inhibition suppresses invasion and vasculogenic mimicry formation of hepatocellular carcinoma cells.
Cheng R; Cai XR; Ke K; Chen YL
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):719-725. PubMed ID: 29058285
[TBL] [Abstract][Full Text] [Related]
13. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
14. BMP2 secretion from hepatocellular carcinoma cell HepG2 enhances angiogenesis and tumor growth in endothelial cells via activation of the MAPK/p38 signaling pathway.
Feng PC; Ke XF; Kuang HL; Pan LL; Ye Q; Wu JB
Stem Cell Res Ther; 2019 Aug; 10(1):237. PubMed ID: 31387619
[TBL] [Abstract][Full Text] [Related]
15. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
16. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y
BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330
[TBL] [Abstract][Full Text] [Related]
17. [Effects of eukaryotic translation initiation factor 5A2 down-regulation by small interfering RNA on aggressiveness of MKN28 human].
Meng QB; Yu JC; Kang WM; Ma ZQ; Zhou L; Ye X; Cao ZJ; Tian SB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Oct; 36(5):482-7. PubMed ID: 25360644
[TBL] [Abstract][Full Text] [Related]
18. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.
Khosravi S; Wong RP; Ardekani GS; Zhang G; Martinka M; Ong CJ; Li G
Br J Cancer; 2014 Jan; 110(2):399-408. PubMed ID: 24178756
[TBL] [Abstract][Full Text] [Related]
19. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
20. Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis
Zhong X; Xiu H; Bi Y; Zhang H; Chang L; Diao H
Bioengineered; 2020 Jan; 11(1):619-627. PubMed ID: 32522053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]